You are here
I have started a petition to keep drugs on the cancer drug fund.
Just for clarification, dasatinib is only being re-evaluated for use in Blast phase, therefore access to dasatinib for treatment of chronic and accelerated is not in question. It is likely that bosutinib will remain on the CDF after re-evaluation although we cannot be certain at this point. Most drugs on the CDF list are included under the heading 'end of life' drugs.
For more detail on the situation of CML drugs on the CDF it might be advisable to read the various threads the have appeared on this forum over recent weeks on the subject of the CDF.
The petition was about all drugs on the cancer drug fund and not any 1 drug in particular so I think that the clarification was unnecessary. The cancer drug fund is for all in Chronic, accelerated and even Blast phase which some of us get to.
As you say Sandy nobody can guarantee anything and surprises come to us all,
Wishing everyone a merry Xmas and a happy new year.